Volume 28, Issue 1 (April 2021)
J Birjand Univ Med Sci. 2021, 28(1): 84-87 |
Back to browse issues page
Research code: 123
Ethics code: 123
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Erfanian N, Miri-Moghaddam E. Treatment of COVID-19 patients using plasma therapy: Letter to Editor. J Birjand Univ Med Sci. 2021; 28 (1) :84-87
URL: http://journal.bums.ac.ir/article-1-2929-en.html
URL: http://journal.bums.ac.ir/article-1-2929-en.html
1- Student Research Committee, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran , nafiseherfanian64@yahoo.com
2- Cardiovascular Diseases Research Center, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
2- Cardiovascular Diseases Research Center, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
Abstract: (2930 Views)
The symptoms of COVID-19, caused by the newly known type of coronavirus, vary widely from asymptomatic, mild to severe respiratory infection leading to hospitalization or death of patients. To date, no specific drug has been reported for the treatment of patients affected by this virus. One of the approaches adopted for the treatment of this disease is the use of plasma therapy, which contains antibodies against the virus. Following of the plasma therapy have not been reported any serious side effects. Currently, the numbers of these studies are limited, and evaluation of the larger population studies can provide stronger evidence for treating physicians about the effectiveness of this therapeutic approach.
Type of Study: Letter to Editor |
Subject:
Immunology
Received: 2020/10/4 | Accepted: 2020/12/18 | ePublished ahead of print: 2021/01/20 | ePublished: 2021/03/5
Received: 2020/10/4 | Accepted: 2020/12/18 | ePublished ahead of print: 2021/01/20 | ePublished: 2021/03/5
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Attribution-NoneCommercial CC BY-NC